Show simple item record

dc.contributor.authorDequen, Pen_GB
dc.contributor.authorLorigan, Paul Cen_GB
dc.contributor.authorJansen, Jen_GB
dc.contributor.authorvan Baardewijk, Men_GB
dc.contributor.authorOuwens, Men_GB
dc.contributor.authorKotapati, Sen_GB
dc.date.accessioned2013-03-22T13:57:46Z
dc.date.available2013-03-22T13:57:46Z
dc.date.issued2012
dc.identifier.citationSystematic review and network meta-analysis of overall survival comparing 3 mg/kg Ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. 2012, 17 (11):1376-85 Oncologisten_GB
dc.identifier.issn1549-490X
dc.identifier.pmid23024154
dc.identifier.doi10.1634/theoncologist.2011-0427
dc.identifier.urihttp://hdl.handle.net/10541/275684
dc.description.abstractTo compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients.
dc.language.isoenen
dc.rightsArchived with thanks to The oncologisten_GB
dc.titleSystematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.en
dc.typeArticleen
dc.contributor.departmentMAPI Group, Houten, The Netherlands.en_GB
dc.identifier.journalThe Oncologisten_GB
html.description.abstractTo compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients.


This item appears in the following Collection(s)

Show simple item record